AARTIPHARM
Aarti Pharmalabs Limited (AARTIPHARM) Stock Analysis
Aarti Pharmalabs Limited is an Indian contract development and manufacturing organization focused on APIs and intermediates. It supplies regulated and niche pharmaceutical ingredients to innovators and generic companies worldwide. The company was carved out from the broader Aarti chemical group and listed separately. It operates manufacturing facilities in India with export-oriented production.
Healthcare › Drug Manufacturers - Specialty & Generic
₹867.60
-8.99% 1W | +7.10% 52W
Market Cap
7.9k CR
P/E Ratio
36.9
52W High
₹1002.4
52W Low
₹585
Div. Yield
0.45%
Beta
0.3
50 DMA
₹861.1
200 DMA
₹740.5
Profit Margin
10.4%
Inst. Own.
12.5%
🔥 APPROACHING RESISTANCE
✅ BOUNCE FROM SUPPORT
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 458 | 440 | 449 | 506 | 555 | 458 | 538 | 564 | 386 | 418 | 432 | 583 | 536 |
| Expenses | 373 | 352 | 353 | 388 | 459 | 364 | 409 | 418 | 293 | 344 | 330 | 470 | 400 |
| Operating Profit | 85 | 88 | 96 | 118 | 96 | 94 | 129 | 146 | 93 | 74 | 102 | 113 | 136 |
| OPM % | 19% | 20% | 21% | 23% | 17% | 20% | 24% | 26% | 24% | 18% | 24% | 19% | 25% |
| Other Income | 0 | 1 | 1 | 2 | 2 | 4 | 5 | -2 | 2 | 0 | 2 | 14 | 8 |
| Interest | 4 | 4 | 4 | 5 | 5 | 6 | 10 | 7 | 7 | 11 | 13 | 17 | 13 |
| Depreciation | 17 | 18 | 19 | 19 | 20 | 21 | 23 | 23 | 23 | 25 | 29 | 28 | 30 |
| Profit before tax | 64 | 67 | 74 | 96 | 74 | 72 | 101 | 115 | 65 | 39 | 63 | 82 | 101 |
| Tax % | 26% | 23% | 29% | 32% | 25% | 24% | 26% | 23% | 24% | 28% | 24% | 25% | 25% |
| Net Profit | 47 | 52 | 53 | 65 | 55 | 55 | 74 | 88 | 50 | 28 | 48 | 61 | 76 |
| EPS in Rs | 5.20 | 5.72 | 5.82 | 7.20 | 6.12 | 6.03 | 8.16 | 9.75 | 5.46 | 3.08 | 5.29 | 6.74 | 8.40 |
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 0 | 1,200 | 1,945 | 1,853 | 2,115 | 1,819 | 1,969 |
| Expenses | 0 | 993 | 1,603 | 1,467 | 1,649 | 1,450 | 1,543 |
| Operating Profit | 0 | 207 | 342 | 386 | 466 | 369 | 426 |
| OPM % | 17% | 18% | 21% | 22% | 20% | 22% | |
| Other Income | 0 | 3 | 2 | 5 | 8 | 15 | 23 |
| Interest | 0 | 12 | 21 | 17 | 27 | 47 | 53 |
| Depreciation | 0 | 42 | 63 | 73 | 87 | 104 | 112 |
| Profit before tax | 0 | 155 | 261 | 300 | 361 | 233 | 284 |
| Tax % | 21% | 26% | 28% | 24% | 25% | ||
| Net Profit | 0 | 122 | 193 | 217 | 272 | 175 | 213 |
| EPS in Rs | 21.35 | 23.93 | 30.05 | 19.27 | 23.51 | ||
| Dividend Payout % | 0% | 9% | 13% | 17% | 18% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | -2.0% | – | – |
| Profit CAGR | -3.0% | – | – |
Shareholding Pattern
Promoters43.72%
FIIs7.34%
DIIs7.80%
Public41.12%
Promoters42.88%
FIIs8.02%
DIIs6.95%
Public42.12%
Promoters43.10%
FIIs7.69%
DIIs7.66%
Public41.54%
Promoters43.08%
FIIs8.39%
DIIs7.40%
Public41.10%
Promoters42.86%
FIIs8.17%
DIIs7.22%
Public41.74%
Promoters45.98%
FIIs7.69%
DIIs13.68%
Public32.64%
Promoters46.46%
FIIs8.33%
DIIs9.97%
Public35.24%
Promoters44.29%
FIIs7.36%
DIIs7.53%
Public40.81%
Promoters43.08%
FIIs8.39%
DIIs7.40%
Public41.10%
Promoters42.86%
FIIs8.17%
DIIs7.22%
Public41.74%
AARTIPHARM
Holdings Analysis
Key strengths & risk signals
54
Overall
39
Fundamental
69
Technical
Risks (2)
Cannot calculate PEG - insufficient growth data.
POSITIVE YEAR! Stock gained 7.1% in the last year.
Strengths (4)
MODERATE STABILITY! 2 revenue dips in history. Acceptable but monitor closely.
BULLISH TREND! 50-day average (861.1) is above 200-day average (740.5) - positive signal.
LOW VOLATILITY! Beta of 0.30 - stable stock, less market risk.
STRONG POSITION! Current price (867.6) is above both moving averages.
Fundamental & Technical Analysis
54Overall
39Fundamental
69Technical
Fundamental Breakdown
Growth Quality
4/30
Revenue CAGR: -2.6% (DECLINING, 2/15). Profit CAGR: -3.3% (DECLINING, 2/15).
Profit Margin
5/10
DECENT EFFICIENCY! 10.4% profit margin - acceptable profitability.
PEG Valuation
1/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.45% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
10/20
SIGNIFICANT PUBLIC HOLDING! 35.92% public ownership - moderate retail influence.
Stability Index
6/10
MODERATE STABILITY! 2 revenue dips in history. Acceptable but monitor closely.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (861.1) is above 200-day average (740.5) - positive signal.
Price Position
8/10
STRONG POSITION! Current price (867.6) is above both moving averages.
Trend Pattern
10/20
AT RESISTANCE! Stock is at key resistance level.
52W Performance
4/10
POSITIVE YEAR! Stock gained 7.1% in the last year.
Volume Sentiment
20/30
BULLISH SENTIMENT! In last 30 days: 17 up days, 13 down days. Avg volume on up days: 806,466 vs down days: 709,162. Ratio: 1.14x
RSI
3/5
NEUTRAL! RSI at 47.3 - balanced momentum.
52W Range
4/5
UPPER HALF! Trading at 67.7% of 52W range - positive territory.
Momentum
3/5
MIXED MOMENTUM! Price growth is inconsistent - -9.0% (1 week), 4.9% (1 month), 20.9% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.30 - stable stock, less market risk.
AARTIPHARM
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q4FY262026-06-01 | Concall PDF | |
| Q3FY262026-02-16 | Concall PDF | |
| Q2FY262025-11-17 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AARTIPHARM | ₹867.60 | 36.9 | 10.4% | -2.6% | -3.3% | +7.1% | 54 | APPROACHING RESISTANCE | +65.4% | +24.5% | +38.7% | -8.0% |
| SUVEN | ₹285.40 | – | – | -19.3% | – | +44.2% | 52 | BREAKDOWN | +147.8% | +179.8% | +89.5% | +140.0% |
| PGHL | ₹5,232.50 | 24.3 | 24.9% | 8.2% | 19.3% | -15.7% | 76 | BREAKOUT | +45.3% | +1.7% | +7.4% | -1.8% |
| SEQUENT | ₹201.20 | 123.4 | 2.5% | 3.1% | -18.9% | +26.2% | 55 | CONSOLIDATION | -13.9% | +161.2% | +10.9% | +102.5% |
| BLISSGVS | ₹660.70 | 52.4 | 13.5% | 7.2% | 22.1% | +342.5% | 73 | BREAKDOWN | +16.5% | +40.7% | +37.6% | +11.1% |
| MOREPENLAB | ₹128.30 | 50.1 | 7.2% | 8.4% | 34.9% | +154.1% | 73 | BREAKDOWN | +427.1% | +259.2% | +34.1% | +17.6% |
| SPARC | ₹191.80 | 3.9 | 83.0% | -45.3% | – | +40.8% | 60 | CONSOLIDATING DOWN | -59.9% | -101.2% | +315.6% | -97.8% |
| IOLCP | ₹203.70 | 35.6 | 6.7% | 1.6% | -0.4% | +99.9% | 58 | BREAKDOWN | +90.0% | +21.1% | +37.1% | +22.1% |
Data from TradeAlone · Updated daily
AARTIPHARM News
Aarti Pharmalabs Limited (AARTIPHARM) clears resistance, gains 11% intraday2026-08-11Aarti Pharmalabs Limited (AARTIPHARM) breaks out, gains 9% intraday2026-08-11Aarti Pharmalabs Limited (AARTIPHARM) breaks out, moves up 20% intraday2026-08-10Aarti Pharmalabs Limited (AARTIPHARM) breaks out, moves up 5% intraday2026-06-23
